MAP1LC3A and cervical cancer: Co-treatment with 3-MA or overexpression of Cdc25A upregulated p62 and FTH1 levels and downregulated the LC3-II/LC-I ratio and TfR1 level in sorafenib-treated cells (Fig. 5A), indicating that overexpression of Cdc25A suppressed sorafenib-induced autophagy in cervical cancer cells.